BR112015020918A2 - métodos para tratar o hcv - Google Patents
métodos para tratar o hcvInfo
- Publication number
- BR112015020918A2 BR112015020918A2 BR112015020918A BR112015020918A BR112015020918A2 BR 112015020918 A2 BR112015020918 A2 BR 112015020918A2 BR 112015020918 A BR112015020918 A BR 112015020918A BR 112015020918 A BR112015020918 A BR 112015020918A BR 112015020918 A2 BR112015020918 A2 BR 112015020918A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hcv
- methods
- weeks
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015020918A2 true BR112015020918A2 (pt) | 2017-07-18 |
Family
ID=50771575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015020918A BR112015020918A2 (pt) | 2013-03-14 | 2014-03-14 | métodos para tratar o hcv |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (enExample) |
| EP (4) | EP3318258B1 (enExample) |
| JP (3) | JP6563894B2 (enExample) |
| KR (2) | KR101853605B1 (enExample) |
| CN (3) | CN108187056A (enExample) |
| AU (3) | AU2014239322B2 (enExample) |
| BR (1) | BR112015020918A2 (enExample) |
| CA (1) | CA2901818C (enExample) |
| CY (1) | CY1121474T1 (enExample) |
| DK (1) | DK2968302T3 (enExample) |
| EA (2) | EA201890507A1 (enExample) |
| ES (1) | ES2654109T3 (enExample) |
| HK (1) | HK1255257A1 (enExample) |
| HR (1) | HRP20171898T1 (enExample) |
| HU (1) | HUE036069T2 (enExample) |
| IL (2) | IL240445B (enExample) |
| LT (1) | LT2968302T (enExample) |
| MX (1) | MX2015012536A (enExample) |
| NO (1) | NO3090119T3 (enExample) |
| PL (1) | PL2968302T4 (enExample) |
| PT (1) | PT2968302T (enExample) |
| RS (1) | RS56735B1 (enExample) |
| SG (2) | SG10201709840UA (enExample) |
| SI (1) | SI2968302T1 (enExample) |
| SM (1) | SMT201800017T1 (enExample) |
| TW (2) | TWI678205B (enExample) |
| WO (1) | WO2014152635A1 (enExample) |
| ZA (1) | ZA201705080B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| EA201890507A1 (ru) * | 2013-03-14 | 2018-07-31 | Эббви Инк. | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv |
| JP2016534082A (ja) * | 2013-10-25 | 2016-11-04 | アッヴィ・インコーポレイテッド | Ｈｃｖの治療方法 |
| US20150174194A1 (en) * | 2013-12-19 | 2015-06-25 | Abbvie Inc. | Methods for treating liver transplant recipients |
| JP6559701B2 (ja) * | 2014-04-02 | 2019-08-14 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置するための方法 |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| CN108778764B (zh) | 2016-01-08 | 2020-09-04 | 恩图鲁斯特咨询卡有限公司 | 具有卡片返回路径的卡片印刷机构 |
| EP3448392A4 (en) | 2016-04-28 | 2020-01-15 | Emory University | ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS |
| WO2018057919A1 (en) * | 2016-09-23 | 2018-03-29 | Abbvie Inc. | Dose adjustment |
| JP2018131439A (ja) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Ｈｃｖを処置する方法 |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
| KR20200140865A (ko) * | 2018-04-10 | 2020-12-16 | 아테아 파마슈티컬즈, 인크. | 간경변증을 갖는 hcv 감염 환자의 치료 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2010153688A (ru) * | 2008-06-10 | 2012-07-20 | Янссен Фармацевтика Нв (Be) | Режим дозирования телапревира |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| PE20110679A1 (es) * | 2009-06-11 | 2011-10-20 | Abbvie Bahamas Ltd | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv |
| PE20140015A1 (es) * | 2010-09-21 | 2014-02-16 | Enanta Pharm Inc | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas |
| CH707030B1 (de) | 2011-10-21 | 2015-03-13 | Abbvie Inc | Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV |
| ES2529143B1 (es) | 2011-10-21 | 2015-10-26 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc |
| EA201890507A1 (ru) * | 2013-03-14 | 2018-07-31 | Эббви Инк. | Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv |
-
2014
- 2014-03-14 EA EA201890507A patent/EA201890507A1/ru unknown
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/pt not_active Application Discontinuation
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/es active Active
- 2014-03-14 HR HRP20171898TT patent/HRP20171898T1/hr unknown
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 TW TW103109528A patent/TWI678205B/zh not_active IP Right Cessation
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/ja not_active Expired - Fee Related
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 EA EA201591701A patent/EA030482B1/ru not_active IP Right Cessation
- 2014-03-14 PL PL14725812T patent/PL2968302T4/pl unknown
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en not_active Ceased
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/lt unknown
- 2014-03-14 SM SM20180017T patent/SMT201800017T1/it unknown
- 2014-03-14 RS RS20171264A patent/RS56735B1/sr unknown
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/es unknown
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 TW TW108114285A patent/TW202002979A/zh unknown
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/zh active Pending
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/ko not_active Expired - Fee Related
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/ko not_active Abandoned
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/hu unknown
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/zh active Pending
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/zh not_active Expired - Fee Related
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 PT PT147258123T patent/PT2968302T/pt unknown
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/el unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/en unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/ja active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/ja active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015020918A2 (pt) | métodos para tratar o hcv | |
| BR112015023017A2 (pt) | combinação de dois antivirais para o tratamento de hepatite c | |
| BR112016022976A8 (pt) | métodos para o tratamento de hcv | |
| BR112014005617A2 (pt) | tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv | |
| PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| BR112018000383A2 (pt) | métodos para tratar hcv | |
| BR112018003232A2 (pt) | terapias de combinação para tratamento de câncer | |
| MX2015017953A (es) | Metodos para tratar el virus de hepatitis c. | |
| BR112014019897A8 (pt) | Espiro[2.4]heptanos para tratamento de infecções por flaviviridae | |
| BR112016013961A2 (pt) | angiotensina ii sozinha ou em combinação para o tratamento da hipotensão | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| BR112019005456A2 (pt) | composição farmacêutica e método para tratamento de esteatose hepática não alcoólica | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| BR102017022849A8 (pt) | Usos terapêuticos de agentes antivirais de ação direta para tratar ou prevenir uma infecção com genótipo 1 a 6 do vírus da hepatite c | |
| BR112017028488A2 (pt) | métodos para tratar hcv | |
| MX2018001905A (es) | Metodos para el tratamiento del virus de hepatitis c (vhc). | |
| BR112014026706A2 (pt) | método de tratamento para dermatoses responsivas a esteroides | |
| BR112018002433A2 (pt) | composição farmacêutica para tratamento da enxaqueca | |
| AU2019384793A8 (en) | Methods for treating acute HCV | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| EA201401274A1 (ru) | Способ комплексного лечения и коррекции нарушений ишемического генеза при резекциях печени | |
| ES2572355A2 (es) | Combinacion de aad para uso en el tratamiento del vhc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |